Latest news

• Novavax announces further delays for regulatory filings of COVID-19 vaccine

  Previously, Novavax’s chief executive officer Stanley Erck said that the company was aiming for a US Food and Drug Administration (FDA) emergency approval of its vaccine – NVX-CoV2373 – as early ... Peak capacity for the vaccine is expected in the

• Novavax is close to finalising a COVID-19 vaccine supply deal with the EU

  Earlier this year, reports emerged that Novavax has encountered issues with sourcing some raw materials used in the manufacturing process for NVX-CoV2373. ... The UK government has already signed an advanced purchase agreement with Novavax for 60 million

• GSK to assist in manufacturing up to 60 million doses of Novavax’s COVID-19 vaccine in the UK

  GlaxoSmithKline (GSK) has signed an agreement to help make up to 60 million doses of Novavax’s COVID-19 vaccine NVX-CoV2373 in the UK. ... The UK government signed an advanced purchase agreement with Novavax in August 2020 for 60 million doses of

• Novavax COVID-19 vaccine found to be 86% effective against UK variant

  Novavax has revealed final efficacy analysis of its COVID-19 vaccine NVX-CoV2373, after reporting interim results from the UK-based phase 3 trial in January. ... Against the B.1.1.7 strain, first identified in the UK, NVX-CoV2373 was found to be 86.3%,

• Novavax to provide 1.1 billion COVID-19 vaccine doses to COVAX

  Novavax has announced that it is to provide 1.1 billion cumulative doses of its COVID-19 vaccine, NVX-CoV2372, to the international vaccines-sharing facility COVAX. ... The doses of NVX-CoV-2373 for COVAX will be manufactured and distributed by Novavax